|
Prostatic Intraepithelial Neoplasias
|
0.300 |
Biomarker
|
disease |
CTD_human |
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.
|
20601956 |
2010 |
|
Leukemia, Monocytic, Chronic
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.
|
16932348 |
2006 |
|
Myeloid Leukemia
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.
|
16932348 |
2006 |
|
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.
|
30804561 |
2019 |
|
Autism Spectrum Disorders
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Tumors with CR showed a significant increase in (P < .05) or trend toward (P < .1) greater (range, 1.49-3.50 fold) pretreatment chemotherapy-sensitivity and mitosis (ATF4, BAX, CCNE1, KIF11, NFX1, PPP3CA, SNX1, TOP2A, and TOP2B) gene mRNA expression compared with tumors with PR, in addition to lower CXCL10 levels (0.48-fold), and had significantly (P < .05) higher (1.65-fold) baseline VEGFA levels.
|
25724086 |
2015 |
|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
There was a statistically significant increase in the TOP2B H-index in locally advanced CaP in comparison with localized tumors (p=0.046).
|
24195515 |
2014 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Further-more, correlation analysis revealed that Topo II alpha expression was correlated with Topo II beta expression in both tumor and normal lung tissues.
|
9765623 |
1998 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
There was no relationship between any of the commonly used pathological variables [tumour size, lymph node status, S-phase fraction (SPF)] and the level of expression of topoisomerase II beta mRNA.
|
8664122 |
1996 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
In contrast to topoisomerase II-alpha, topoisomerase II-beta was expressed in most normal as well as in tumor tissue samples, at a similar level.
|
8547322 |
1995 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We used cell viability assays, western blotting, and EdU proliferation assay combined with calcein-AM treatment or siRNA interference to investigate the role of topoisomerase IIβ binding protein 1 (TopBP1) and p53 in NSCLC chemotherapy.
|
28628491 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In a contrast, high expression of isoforms TOP1 and TOP2B indicated better OS in all NSCLC and Ade, but not in SCC patients.
|
28355294 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
|
23696245 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.
|
22627319 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
NUP98 is fused to topoisomerase (DNA) IIbeta 180 kDa (TOP2B) in a patient with acute myeloid leukemia with a new t(3;11)(p24;p15).
|
16166424 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
There were no significant differences in Topo II beta gene expression between tumors and normal lung tissues and between SCLC and NSCLC.
|
9765623 |
1998 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
For investigation of relative differences in mRNA expression levels and of correlations in the expression of genes possibly involved in multidrug resistance (MDR) of acute myelogenous leukemias (AML), a complementary DNA polymerase chain reaction (cDNA-PCR) analysis was established for the genes encoding MDR1/P-glycoprotein, the multidrug resistance-associated protein (MRP), topoisomerase II alpha, topoisomerase II beta, topoisomerase I, glutathione S-transferase pi, protein kinase C (PKC) isozymes alpha, beta 1, beta 2, epsilon, eta, theta and cyclin A.
|
8642857 |
1996 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
(1) the two isoforms of topoisomerase II are differentially expressed in normal lung and NSCLC cells; (2) higher topoisomerase II-alpha expression is associated with higher cell proliferation in NSCLC; (3) the expression of topoisomerase II-alpha and topoisomerase I, but not of topoisomerase II-beta, was higher in tumor cells compared to normal lung.
|
8547322 |
1995 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
The results indicate that detection of the TMPRSS2-ERG fusion gene and parallel immunohistochemical examination of AR, TOP2B and ERG has diagnostic significance and may be useful in assessing the biological character of the prostate cancer as well as selecting the best treatment.
|
24195515 |
2014 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we hypothesize that these transcription-induced, TOP2B-mediated DSBs can also be exploited therapeutically and propose that, in hormone-dependent tumors like breast and prostate cancers, a hormone-cycling therapy, in combination with topoisomerase II poisons or inhibitors of the DNA repair components PARP1 and DNA-PK, could overwhelm cancer cells with transcription-associated DSBs.
|
21385925 |
2011 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.
|
20601956 |
2010 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
This review discusses origin of Topoisomerase II beta, its structure, activities reported in vitro and in vivo along with implications in cellular processes namely transcription, DNA repair, neuronal development, aging, HIV-infection and cancer.
|
28669856 |
2017 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Besides the most common hypothesis that anthracycline-induced congestive heart failure (CHF) is mainly caused by generation of reactive oxygen species, recent data point to a critical role of topoisomerase II beta (TOP2B), which is a primary target of anthracycline poisoning, in the pathophysiology of CHF.
|
28102848 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
This review discusses origin of Topoisomerase II beta, its structure, activities reported in vitro and in vivo along with implications in cellular processes namely transcription, DNA repair, neuronal development, aging, HIV-infection and cancer.
|
28669856 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Topoisomerase IIβ-binding protein 1 (TOPBP1) participates in DNA replication and DNA damage response; however, its role in DNA repair and relevance for human cancer remain unclear.
|
26811421 |
2016 |